Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06041269 · ClinicalTrials.gov registry record · Phase 2
A Study of Efficacy and Safety of Rosnilimab in Subjects with Moderate to Severe Rheumatoid Arthritis (RENOIR)
A Phase 2 study of Rheumatoid Arthritis, sponsored by AnaptysBio.
- Active
- Registry status
- Phase 2
- Development phase
- 420
- Enrollment target
- 20
- Study locations
NCT06041269 is a Phase 2 study of Rheumatoid Arthritis that is active but no longer recruiting, run by AnaptysBio. The registered enrollment target is 420 participants, below the 4,688-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (91% lower). The trial reports 20 study locations across 3 states.
The verdict
NCT06041269, a Phase 2 study of Rheumatoid Arthritis, is active but no longer recruiting, sponsored by AnaptysBio.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 420 participants
- Enrollment target
- 20
- Study locations
Study Summary
RENOIR Study: This study will evaluate the safety, tolerability, and efficacy of Rosnilimab in subjects with moderate to severe Rheumatoid Arthritis (RA)
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Rosnilimab
Study Locations (20)
Florida
- AnaptysBio Investigative Site 10-103 - Aventura
- AnaptysBio Investigative Site 10-141 - Avon Park
- AnaptysBio Investigative Site 10-118 - Boynton Beach
- AnaptysBio Investigative Site 10-125 - Daytona Beach
- AnaptysBio Investigative Site 10-122 - Homestead
- Anaptys Bio Investigative Site 10-142 - Miami
- AnaptysBio Investigative Site 10-140 - Miami
- AnaptysBio Investigative Site 10-102 - Miami
- AnaptysBio Investigative Site 10-124 - Plantation
California
- AnaptysBio Investigative Site 10-105 - Covina
- Anaptys Bio Investigative Site 10-119 - Rancho Mirage
- AnaptysBio Investigative Site 10-113 - San Diego
- AnaptysBio Investigative Site 10-127 - San Francisco
- AnaptysBio Investigative Site 10-136 - Temecula
- AnaptysBio Investigative Site 10-133 - Upland
- AnaptysBio Investigative Site 10-112 - Whitter
Arizona
- AnaptysBio Investigative Site 10-132 - Flagstaff
- AnaptysBio Investigative Site 10-130 - Glendale
- AnaptysBio Investigative Site 10-129 - Phoenix
- AnaptysBio Investigative Site 10-131 - Tucson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 420 participants |
| Start Date | 2023-08-31 |
| Est. Completion | 2025-05-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06041269
The ClinicalTrials.gov registry entry for NCT06041269 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 420 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,688-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (91% lower). The listed sponsor is AnaptysBio, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Rheumatoid Arthritis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06041269 reports 20 study locations spanning 3 distinct geographic areas - top geographies include Florida, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT06041269 about?
NCT06041269 is a clinical study titled "A Study of Efficacy and Safety of Rosnilimab in Subjects with Moderate to Severe Rheumatoid Arthritis (RENOIR)". RENOIR Study: This study will evaluate the safety, tolerability, and efficacy of Rosnilimab in subjects with moderate to severe Rheumatoid Arthritis (RA)
What is the current status of trial NCT06041269?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 420 participants. The study started on 2023-08-31. Estimated completion is 2025-05-30.
What conditions does trial NCT06041269 study?
This clinical trial studies the following conditions: Rheumatoid Arthritis.
What interventions are being tested in trial NCT06041269?
The interventions under investigation include: Placebo (DRUG), Rosnilimab (DRUG).
Who is sponsoring clinical trial NCT06041269?
This trial is sponsored by AnaptysBio, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06041269 being conducted?
This trial has 20 study locations across Arizona, California, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rheumatoid Arthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of SPY072 in Rheumatic Disease
RECRUITING · Phase 2
-
Dynamic Treatment Regiments for Glucocorticoid Tapering
RECRUITING · Phase 2
-
A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis
RECRUITING · Phase 2
-
A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis
RECRUITING · Phase 2
-
A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors)
RECRUITING · Phase 2
-
An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.